The Priority Review

Tag

Psoriatic Arthritis

1 story

  1. Clinical trials

    Takeda registers Phase 3b trial of Zasocitinib in psoriatic arthritis

    Takeda plans to enroll 644 participants in a Phase 3b study of Zasocitinib (TAK-279) for active psoriatic arthritis, with a start date of January 11, 2027. The trial is expected to reach primary completion on April 18, 2030.